Durable Improvement in Patient Reported Outcomes across DLQI Subdomains Over 48 Weeks in Chronic Plaque Psoriasis Patients Treated With Certolizumab Pegol in Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2). J of Skin 2019, 3 (2), 175. https://doi.org/10.25251/skin.3.2.15.